• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Iron-chelation therapy with oral deferiprone--toxicity or lack of efficacy?

作者信息

Kowdley K V, Kaplan M M

出版信息

N Engl J Med. 1998 Aug 13;339(7):468-9. doi: 10.1056/NEJM199808133390709.

DOI:10.1056/NEJM199808133390709
PMID:9700182
Abstract
摘要

相似文献

1
Iron-chelation therapy with oral deferiprone--toxicity or lack of efficacy?
N Engl J Med. 1998 Aug 13;339(7):468-9. doi: 10.1056/NEJM199808133390709.
2
Iron chelation with oral deferiprone in patients with thalassemia.
N Engl J Med. 1998 Dec 3;339(23):1712; author reply 1713-4.
3
Iron chelation with oral deferiprone in patients with thalassemia.
N Engl J Med. 1998 Dec 3;339(23):1711-2; author reply 1713-4.
4
Iron chelation with oral deferiprone in patients with thalassemia.
N Engl J Med. 1998 Dec 3;339(23):1710; author reply 1713-4. doi: 10.1056/NEJM199812033392313.
5
Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major.去铁酮用于重型地中海贫血的铁螯合疗法的长期安全性和有效性
N Engl J Med. 1998 Aug 13;339(7):417-23. doi: 10.1056/NEJM199808133390701.
6
Iron chelation with oral deferiprone in patients with thalassemia.
N Engl J Med. 1998 Dec 3;339(23):1712-3; author reply 1713-4.
7
Iron chelation with oral deferiprone in patients with thalassemia.
N Engl J Med. 1998 Dec 3;339(23):1710-1; author reply 1713-4.
8
Iron chelation with oral deferiprone in patients with thalassemia.
N Engl J Med. 1998 Dec 3;339(23):1712; author reply 1713-4.
9
Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients.重型地中海贫血患者长期使用去铁酮治疗期间的肝纤维化和铁水平
Hemoglobin. 2006;30(2):215-8. doi: 10.1080/03630260600642534.
10
A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.一项使用心血管磁共振评估去铁胺与去铁酮联合治疗对重型地中海贫血患者心肌铁影响的随机、安慰剂对照、双盲试验。
Circulation. 2007 Apr 10;115(14):1876-84. doi: 10.1161/CIRCULATIONAHA.106.648790. Epub 2007 Mar 19.

引用本文的文献

1
Disposal of iron by a mutant form of lipocalin 2.载脂蛋白 2 突变体形式对铁的处理。
Nat Commun. 2016 Oct 31;7:12973. doi: 10.1038/ncomms12973.
2
World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients.全球健康困境：孤儿病与罕见病、孤儿药与孤儿患者
World J Methodol. 2014 Sep 26;4(3):163-88. doi: 10.5662/wjm.v4.i3.163.
3
The exochelins of pathogenic mycobacteria: unique, highly potent, lipid- and water-soluble hexadentate iron chelators with multiple potential therapeutic uses.致病性分枝杆菌的外螯菌素：独特、高效、脂溶性和水溶性兼具的六齿铁螯合剂，具有多种潜在治疗用途。
Antioxid Redox Signal. 2014 Dec 1;21(16):2246-61. doi: 10.1089/ars.2013.5789. Epub 2014 Jun 20.
4
Deferiprone in the treatment of transfusion-dependent thalassemia: a review and perspective.地拉罗司治疗输血依赖型地中海贫血：综述与展望。
Ther Clin Risk Manag. 2007 Oct;3(5):795-805.
5
Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.去铁酮治疗地中海贫血及其他病症铁过载的获益与风险：与去铁胺的流行病学及治疗学方面比较
Drug Saf. 2003;26(8):553-84. doi: 10.2165/00002018-200326080-00003.
6
Clinical research: a tale of two studies.临床研究：两项研究的故事。
Trans Am Clin Climatol Assoc. 2003;114:219-30; discussion 230-2.
7
Iron toxicity and chelation therapy.铁中毒与螯合疗法。
Int J Hematol. 2002 Oct;76(3):219-28. doi: 10.1007/BF02982791.
8
Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases.去铁酮：对其在重型β地中海贫血及其他依赖输血疾病的铁过载中临床潜力的综述
Drugs. 1999 Sep;58(3):553-78. doi: 10.2165/00003495-199958030-00021.
9
Constraints of interest: lessons at the Hospital for Sick Children.关注的限制因素：病童医院的经验教训
CMAJ. 1998 Oct 20;159(8):955-7.